Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06962657 · ClinicalTrials.gov registry record · Phase 2
Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection
A Phase 2 study, sponsored by University of California, San Diego.
- Not yet
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT06962657 is a Phase 2 study that has not yet begun recruiting, run by University of California, San Diego. The registered enrollment target is 20 participants.
The verdict
NCT06962657, a Phase 2 study, has not yet begun recruiting, sponsored by University of California, San Diego.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
This research study is being conducted to see if coenzyme Q10 (a nutritional supplement) might help to prevent and/or alleviate symptoms and health consequences and help to improve quality of life and physical function in residents affected by the February 2023 East Palestine, Ohio train derailment. This is a pilot study that is not powered to achieve benefit but seek to examine effect size and variance to aid in power calculations for a potential future better powered study.
Interventions
- DRUG Placebo
- DRUG Ubiquinone 100 mg Oral Soft Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-05-15 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06962657
The ClinicalTrials.gov registry entry for NCT06962657 describes a study currently listed as not yet recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06962657 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06962657 about?
NCT06962657 is a clinical study titled "Mitigating Toxic Impact: The Role of Coenzyme Q10 in Post-Exposure Protection". This research study is being conducted to see if coenzyme Q10 (a nutritional supplement) might help to prevent and/or alleviate symptoms and health consequences and help to improve quality of life and physical function in residents affected by the February 2023 East Palestine, Ohio train derailment....
What is the current status of trial NCT06962657?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-05-15. Estimated completion is 2028-10-01.
What interventions are being tested in trial NCT06962657?
The interventions under investigation include: Placebo (DRUG), Ubiquinone 100 mg Oral Soft Gel (DRUG).
Who is sponsoring clinical trial NCT06962657?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.